Profile data is unavailable for this security.
About the company
Aarti Pharmalabs Limited is a manufacturer of active pharmaceutical ingredients (API), pharmaceutical intermediates, new chemical entities (NCE), xanthine derivatives, and allied products, situated in India. The Company delivers contract development and manufacturing organization (CDMO) services for drug substance/NCE development and manufacturing for pharmaceutical and biotech firms with a focus on the Ph-I/II/III, launch, and commercial phases. It has dedicated facilities for the production of corticosteroids, cytotoxic medicines, and oncology products. Its range of API products include Ramipril, Quinapril HCL, Budesonide, Bambuterol HCL, Apixaban, Rivaroxaban, Cinacalcet and others. Its range of intermediate products include Abemaciclib Intermediate, Acalabrutinib Intermediate, Afatinib Intermediate, Apalutamide Intermediate, Azathioprine Intermediate, and others. Its Caffeine products include caffeine anhydrous, and caffeine anhydrous (granules).
- Revenue in INR (TTM)18.53bn
- Net income in INR2.17bn
- Incorporated2019
- Employees1.40k
- LocationAarti Pharmalabs LtdMUMBAI 400080IndiaIND
- Phone+91 2 269436100
- Fax+91 2 267976660
- Websitehttps://www.aartipharmalabs.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indoco Remedies Ltd | 18.17bn | 984.70m | 30.07bn | 6.10k | 31.00 | 2.71 | 15.92 | 1.65 | 10.52 | 10.52 | 193.15 | 120.38 | 0.9557 | 1.65 | 4.80 | -- | 5.10 | 6.88 | 7.02 | 9.85 | 69.23 | 66.66 | 5.34 | 6.93 | 0.9825 | 4.01 | 0.377 | 12.67 | 8.91 | 13.41 | -30.78 | -- | 34.54 | 37.97 |
| SeQuent Scientific Ltd | 13.70bn | -358.69m | 30.60bn | 478.00 | -- | 4.66 | 95.83 | 2.23 | -1.45 | -1.45 | 56.27 | 26.37 | 0.8925 | 2.19 | 4.05 | -- | -1.93 | 1.09 | -3.27 | 1.76 | 44.53 | 42.74 | -2.16 | 1.18 | 0.7602 | 0.1376 | 0.4062 | -- | -3.60 | 5.68 | 70.40 | -- | 6.96 | -- |
| Supriya Lifescience Ltd | 5.70bn | 1.19bn | 32.06bn | 392.00 | 26.92 | 3.93 | 23.76 | 5.62 | 14.80 | 14.80 | 70.87 | 101.31 | 0.655 | 2.21 | 5.81 | -- | 13.68 | 19.08 | 15.19 | 24.04 | 61.12 | 58.71 | 20.88 | 24.71 | 4.06 | 66.40 | 0.0067 | 2.88 | 23.74 | 15.47 | 32.56 | 24.75 | 83.79 | -- |
| Gufic BioSciences Ltd | 8.07bn | 861.36m | 35.78bn | 1.63k | 40.78 | 6.72 | 34.69 | 4.44 | 8.75 | 8.75 | 81.90 | 53.11 | 0.8258 | 2.03 | 3.01 | -- | 8.82 | 11.46 | 13.32 | 19.21 | 51.67 | 46.99 | 10.68 | 10.46 | 1.08 | 8.37 | 0.3847 | -- | 16.80 | 18.12 | 8.07 | 31.46 | 53.83 | 14.87 |
| Hikal Ltd | 17.85bn | 696.00m | 36.84bn | 2.14k | 52.88 | 3.10 | 19.68 | 2.06 | 5.65 | 5.65 | 144.77 | 96.32 | 0.7325 | 2.66 | 3.60 | -- | 2.86 | 5.07 | 4.03 | 7.51 | 53.79 | 47.22 | 3.90 | 5.86 | 0.8761 | 2.65 | 0.4077 | 16.88 | -11.79 | 2.34 | -11.20 | -7.55 | 9.72 | 0.00 |
| Unichem Laboratories Ltd | 17.05bn | -704.74m | 38.74bn | 3.12k | -- | 1.64 | 90.59 | 2.27 | -10.02 | -10.02 | 238.88 | 335.54 | 0.5359 | 0.9995 | 2.84 | -- | -2.22 | -1.67 | -2.81 | -2.03 | 61.02 | 57.79 | -4.13 | -3.99 | 1.40 | -0.5733 | 0.0948 | -- | 26.94 | 7.64 | 65.15 | -- | -35.00 | -- |
| Advanced Enzyme Technologies Ltd | 6.24bn | 1.33bn | 44.16bn | 338.00 | 33.11 | 3.34 | 25.65 | 7.08 | 11.93 | 11.93 | 55.83 | 118.41 | 0.4219 | 1.06 | 6.27 | -- | 9.26 | 10.82 | 10.23 | 11.93 | 76.83 | 72.81 | 21.95 | 24.59 | 6.22 | 57.81 | 0.0334 | 15.17 | 15.39 | 8.26 | 26.19 | 3.72 | 27.85 | 53.42 |
| Aarti Drugs Ltd | 25.29bn | 1.71bn | 47.92bn | 1.50k | 28.01 | 3.74 | 21.48 | 1.90 | 18.61 | 18.61 | 274.44 | 139.40 | 1.04 | 3.35 | 3.22 | -- | 7.07 | 9.73 | 10.98 | 15.74 | 33.65 | 24.96 | 6.79 | 8.25 | 1.05 | 7.91 | 0.3056 | -- | -6.90 | 10.13 | 3.07 | 13.82 | 24.96 | -- |
| Shilpa Medicare Ltd | 11.51bn | 318.74m | 52.13bn | 1.03k | 144.85 | 2.56 | 37.28 | 4.53 | 3.68 | 3.68 | 134.51 | 208.37 | 0.3841 | 1.23 | 3.21 | -- | 1.07 | 2.84 | 1.41 | 3.65 | 64.63 | 61.37 | 2.78 | 7.03 | 0.7671 | 1.41 | 0.3424 | -- | 9.66 | 9.44 | 198.15 | -22.26 | -9.26 | -- |
| Orchid Pharma Ltd | 8.19bn | 915.95m | 53.65bn | 838.00 | 55.27 | 4.59 | 42.00 | 6.55 | 19.14 | 19.14 | 169.90 | 230.58 | 0.5897 | 1.97 | 3.99 | -- | 6.80 | -0.9734 | 8.80 | -1.40 | 40.87 | 43.32 | 11.53 | -2.40 | 2.03 | 4.68 | 0.1031 | -- | 23.05 | 6.43 | 73.59 | 5.84 | 57.79 | -- |
| Aarti Pharmalabs Ltd | 18.53bn | 2.17bn | 54.93bn | 1.40k | 25.32 | 3.13 | 18.93 | 2.97 | 23.94 | 23.94 | 204.45 | 193.89 | 0.7698 | 1.64 | 3.86 | -- | 9.01 | -- | 12.30 | -- | 44.90 | -- | 11.71 | -- | 1.01 | 18.17 | 0.1397 | -- | -4.76 | -- | 12.10 | -- | -- | -- |
| Blue Jet Healthcare Ltd | 7.12bn | 1.64bn | 67.99bn | -- | 41.50 | 8.04 | 35.44 | 9.55 | 9.44 | 9.44 | 41.04 | 48.73 | 0.7409 | 2.46 | 3.42 | -- | 17.05 | -- | 21.25 | -- | 55.82 | -- | 23.01 | -- | 2.80 | 1,257.13 | 0.00 | -- | -1.30 | -- | 2.33 | -- | -- | -- |
| Marksans Pharma Ltd | 21.77bn | 3.14bn | 72.88bn | 1.40k | 23.21 | 3.53 | 18.73 | 3.35 | 6.93 | 6.93 | 48.11 | 45.57 | 0.894 | 1.88 | 5.01 | -- | 12.93 | 14.62 | 15.36 | 18.52 | 52.32 | 51.22 | 14.46 | 14.03 | 3.19 | 34.30 | 0.1048 | 6.66 | 17.56 | 16.84 | 17.80 | 32.62 | 73.86 | 64.38 |
| F D C Ltd | 19.43bn | 3.05bn | 75.10bn | 6.37k | 24.79 | 3.58 | 21.77 | 3.87 | 18.61 | 18.61 | 118.69 | 128.81 | 0.8077 | 1.83 | 16.19 | -- | 12.68 | 12.05 | 14.56 | 13.73 | 66.23 | 62.81 | 15.70 | 15.85 | 2.18 | 74.02 | 0.0097 | -- | 8.92 | 12.24 | 57.30 | 12.45 | 16.93 | -- |
| Sun Pharma Advanced Research Co Ltd | 755.50m | -3.87bn | 76.03bn | 407.00 | -- | 60.46 | -- | 100.63 | -11.93 | -11.93 | 2.33 | 3.87 | 0.1123 | -- | 3.13 | -- | -57.57 | -61.70 | -85.93 | -119.31 | 62.77 | 76.08 | -512.52 | -163.40 | -- | -245.33 | 0.3414 | -- | -68.36 | -16.20 | -73.96 | -- | 15.40 | -- |
Data as of Jun 14 2024. Currency figures normalised to Aarti Pharmalabs Ltd's reporting currency: Indian Rupee INR
7.24%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| quant Money Managers Ltd.as of 31 May 2024 | 1.88m | 2.08% |
| Morgan Stanley Investment Management Co.as of 31 Mar 2024 | 974.85k | 1.08% |
| BAMCO, Inc.as of 30 Apr 2024 | 876.36k | 0.97% |
| BlackRock Fund Advisorsas of 09 May 2024 | 733.15k | 0.81% |
| ICICI Prudential Asset Management Co. Ltd.as of 30 Apr 2024 | 599.33k | 0.66% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 30 Apr 2024 | 496.33k | 0.55% |
| Dimensional Fund Advisors LPas of 09 May 2024 | 443.79k | 0.49% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 341.42k | 0.38% |
| BlackRock Advisors (UK) Ltd.as of 09 May 2024 | 133.58k | 0.15% |
| Motilal Oswal Asset Management Co. Ltd.as of 30 Apr 2024 | 80.35k | 0.09% |
More ▼
Data from 31 Dec 2023 - 31 May 2024Source: FactSet Research Systems Inc.
